Keros Therapeutics Appoints Experienced Healthcare Finance Executive Charles Newton to Board

summarizeSummary

Keros Therapeutics announced the appointment of Charles Newton, a seasoned healthcare finance executive and former CFO of Lyell Immunopharma, to its Board of Directors, while Dr. Carl Gordon will resign.

check_boxKey Events

• New Director Appointed

  Charles Newton, former CFO of Lyell Immunopharma and a veteran in healthcare investment banking, joins the Board of Directors effective March 9, 2026.

• Board Committee Appointments

  Mr. Newton will serve on both the Compensation Committee and the Audit Committee.

• Director Resignation

  Dr. Carl Gordon will resign from the Board and Compensation Committee, effective March 9, 2026, with no stated disagreements.

• Director Compensation

  Mr. Newton will receive standard non-employee director compensation, including initial equity grants valued at $300,000 and annual cash and equity retainers.

auto_awesomeAnalysis

The appointment of Charles Newton significantly strengthens Keros Therapeutics' board with his extensive background in healthcare investment banking and as a former CFO of a biopharma company. His expertise in capital markets and navigating clinical program value inflection points will be invaluable as Keros advances its pipeline. The simultaneous resignation of Dr. Carl Gordon is noted as not being due to any disagreement, indicating a smooth transition rather than a concerning departure. This move enhances corporate governance and strategic financial oversight for the clinical-stage biopharmaceutical company.